The group of researchers is now analyzing the data to see if those on GLP-1s who developed cancer have a significant difference in cancer outcomes compared with those with cancer but not taking a GLP-1
doi:10.1177/0269881119857204 Grinspoon, P., MD
The rollercoaster history of using physiological and pharmacological properties of incretin hormones to develop diabetes medications with a convincing benefitrisk relationship
These medications regulate blood sugar levels, manage body weight, and promote overall health
6 Supply chain limitations, high production costs, and the need for specialized facilities restrict the scalability of these drugs
Data were pooled using random-effects models with subgroup analyses by drug type and treatment duration (3, 6, and 12 months)